Episode Details

Eli Lilly’s stock soars past $1,150, fueled by explosive growth in its GLP-1 drugs—Mounjaro and Zepbound—and a major new development: FDA approval for Foundayo, the first pill version of their therapy. This could unlock massive new patient access and extend their growth runway. Q1 results smashed expectations with 56% revenue and 156% EPS growth, plus a bold revenue guidance bump. The real test comes August 5th, when investors will watch for Foundayo adoption, Zepbound supply updates, and whether they’ll raise guidance again. With $750M in U.S. manufacturing expansion, aggressive M&A, and AI-driven drug discovery on the horizon, Eli Lilly is clearly building for sustained dominance.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/3041b8581ef2b8a6